ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 81 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q2 2020. The put-call ratio across all filers is 1.08 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $237,000 | +7.7% | 45,900 | -11.4% | 0.00% | – |
| Q2 2021 | $220,000 | +197.3% | 51,800 | +275.4% | 0.00% | – |
| Q1 2021 | $74,000 | -68.0% | 13,800 | +76.9% | 0.00% | – |
| Q4 2020 | $231,000 | +272.6% | 7,800 | 0.0% | 0.00% | – |
| Q3 2020 | $62,000 | -47.5% | 7,800 | -33.9% | 0.00% | – |
| Q2 2020 | $118,000 | +637.5% | 11,800 | +100.0% | 0.00% | – |
| Q1 2020 | $16,000 | +128.6% | 5,900 | 0.0% | 0.00% | – |
| Q4 2019 | $7,000 | – | 5,900 | +3370.6% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 170 | -91.1% | 0.00% | – |
| Q2 2019 | $8,000 | 0.0% | 1,900 | 0.0% | 0.00% | – |
| Q1 2019 | $8,000 | +60.0% | 1,900 | +100.0% | 0.00% | – |
| Q4 2018 | $5,000 | -61.5% | 950 | 0.0% | 0.00% | – |
| Q3 2018 | $13,000 | +18.2% | 950 | 0.0% | 0.00% | – |
| Q2 2018 | $11,000 | 0.0% | 950 | 0.0% | 0.00% | – |
| Q1 2018 | $11,000 | +83.3% | 950 | 0.0% | 0.00% | – |
| Q4 2017 | $6,000 | – | 950 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $2,341,000 | 3.33% |
| Matrix Capital Management Company, LP | 38,974,185 | $66,256,000 | 1.50% |
| NEA Management Company, LLC | 17,082,612 | $29,040,000 | 1.49% |
| Endurant Capital Management LP | 1,824,065 | $3,101,000 | 1.09% |
| Long Focus Capital Management, LLC | 4,679,491 | $7,955,000 | 0.83% |
| Key Client Fiduciary Advisors, LLC | 416,166 | $707,000 | 0.69% |
| PFM Health Sciences, LP | 9,109,780 | $15,487,000 | 0.59% |
| ACT CAPITAL MANAGEMENT, LLC | 90,000 | $153,000 | 0.21% |
| DAFNA Capital Management LLC | 351,064 | $597,000 | 0.16% |
| Rock Springs Capital Management LP | 2,357,544 | $4,008,000 | 0.12% |